News from decision resources A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( TorontoVE:AUT)

Nov 19, 2014, 11:45 ET
Decision Resources Group Logo

The First Class of Biosimilars to Enter the U.S. Market Will Generate $1.8 Billion by 2023

 Decision Resources Group finds that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim, which is...

Nov 18, 2014, 11:00 ET
Decision Resources Group Logo.

Zytiga is Currently the Most Commonly Prescribed Second-Line Therapy for Metastatic Castrate-Resistant Prostate Cancer, According to Surveyed European Oncologists

 Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for...

Nov 12, 2014, 12:00 ET
Decision Resources Group Logo

Medtronic and St. Jude Medical Dominate the European Pain Management Device Market

 Decision Resources Group finds that the European pain management device market generates a majority of revenue from select products, such as...

Nov 12, 2014, 11:00 ET
Decision Resources Group Logo.

The Ulcerative Colitis Market Will Grow Over the Next Decade, Reaching $4.2 Billion in 2023

Decision Resources Group finds that the ulcerative colitis (UC) market will grow over the next decade from $2.7 billion in 2013 to $4.2 billion in...

Nov 12, 2014, 10:00 ET
Decision Resources Group Logo

Launch of Novel Oral HIF-PH Inhibitors Will Intensify the Competition for Renal Anemia Patient Share

 Decision Resources Group finds that surveyed nephrologists expect hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHi) to capture...

Nov 11, 2014, 14:00 ET
Decision Resources Group Logo.

Surveyed Endocrinologists in Europe and the United States Only Expect to Switch a Minority of Their Patients Currently Receiving Lantus to Biosimilar Insulin Glargine

Decision Resources Group finds that surveyed endocrinologists in the United States, France and Germany expect to switch less than one-third of...

Nov 11, 2014, 10:00 ET
Decision Resources Group Logo

U.S. Healthcare Reform Presents Challenges to the Diagnostic Imaging System Market, Resulting in Only Modest Growth Through 2023

 Decision Resources Group finds that the diagnostic imaging system market in the United States is being hindered by ongoing healthcare reform...

Nov 06, 2014, 11:00 ET
Decision Resources Group Logo.

Surveyed U.S. Specialists Perceive Gilead's Harvoni, the First Single-Tablet Regimen for Hepatitis C Virus Infections, As Having Key Advantages Over Emerging Treatment Options

Decision Resources Group finds that surveyed specialists anticipate prescribing Gilead's Harvoni to a high proportion of their genotype-1 infected...

Nov 06, 2014, 10:00 ET
Decision Resources Group Logo

U.S. Minimally Invasive Spine Technology Market To Grow at Almost 6 Percent Annually Through 2023, Much Faster than the Traditional Open Spinal Implant Market

 Decision Resources Group finds that the United States minimally invasive spine technology market will grow at approximately 6 percent annually...

Nov 05, 2014, 11:57 ET
Decision Resources Group Logo

In The Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to $10.7 Billion in 2023

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis...

Nov 05, 2014, 10:00 ET
Decision Resources Group Logo

Asia Pacific Electrophysiology Mapping and Ablation Device Market Will Reach Nearly $1.3 Billion by 2023

 Decision Resources Group finds that the Asia Pacific electrophysiology (EP) mapping and ablation device market will grow strongly through 2023...

Nov 04, 2014, 11:30 ET
Decision Resources Group Logo.

Increased Scrutiny by EU5 Health Authorities Will Encourage Use of Off-label Avastin and Emerging Biosimilars in the European Wet Age-Related Macular Degeneration Market

Decision Resources Group finds that the cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) are...

Nov 04, 2014, 10:00 ET
Decision Resources Group

U.S. Orthopedic Soft Tissue Solutions Market Will Increase to More Than $3 Billion by 2023

Decision Resources Group finds that the orthopedic soft tissue solutions market in the United States will increase to more than $3 billion by 2023....

Nov 03, 2014, 12:24 ET
Decision Resources Group Logo.

U.S. Breast Implant and Reconstructive Device Market Will Grow Modestly in the Next Few Years, While European Market Will Decline Until the Economy Recovers

Decision Resources Group finds that the United States and European breast implant and reconstructive device market will expand modestly through...

Nov 03, 2014, 11:00 ET
Decision Resources Group Logo.

Diabetic Nephropathy is Considered the Renal Disease with the Greatest Unmet Need for New Therapeutic Options

Decision Resources Group finds that among all physician specialties, diabetic nephropathy (DN) is considered the renal disease with the greatest...

Oct 30, 2014, 13:00 ET
Decision Resources Group Logo.

In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan

 Decision Resources Group finds that Medivation/Astellas Pharma's Xtandi will be the sales-leading agent across the world's major markets for...

Oct 30, 2014, 12:45 ET
Decision Resources Group Logo.

Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers

Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia,...

Oct 29, 2014, 14:07 ET
Decision Resources Group Logo.

U.S. Physicians and Payers are Generally Positive About the Efficacy of Pfizer's Xeljanz for Treating RA But They Have Mixed Views About Its Effect on Structural Damage and Safety

 Decision Resources Group finds that although 80 percent of surveyed rheumatologists currently prescribe Pfizer's Xeljanz for the treatment of...

Oct 29, 2014, 12:00 ET
Decision Resources Group Logo.

The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs

 Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's...

Oct 29, 2014, 10:00 ET
Decision Resources Group Logo.

U.S. Surgical Hemostat, Internal Tissue Sealant and Adhesion Barrier Market to Reach Nearly $2.9 Billion

 Decision Resources Group finds that the United States market for surgical hemostats, internal tissue sealants and adhesion barriers will grow...